Package Leaflet: Information for the Patient

Duvyzat® 8.86 mg/ml oral suspension

givinostat

Select your language:
(472KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(447KB – PDF)
First publication 15/07/2025
Last update 31/07/2025
(453KB – PDF)
First publication 15/07/2025
Last update 31/07/2025
(419KB – PDF)
First publication 15/07/2025
Last update 31/07/2025
(456KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(468KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(493KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(434KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(418KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(434KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(452KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(472KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(468KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(525KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(482KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(407KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(376KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(414KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(483KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(472KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(468KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(452KB – PDF)
First publication 15/07/2025
Last update 31/07/2025
(418KB – PDF)
First publication 15/07/2025
Last update 31/07/2025
(481KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(446KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(429KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(469KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(428KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(474KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(461KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(507KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(422KB – PDF)
First publication 15/07/2025
Last update 21/07/2025
(446KB – PDF)
First publication 15/07/2025
Last update 21/07/2025

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Scroll to Top

You are now leaving this webpage and will be redirected to the Italfarmaco website to access pharmacovigilance services.